Lipocine (NASDAQ:LPCN) Stock Passes Below 200 Day Moving Average – Here’s Why

Shares of Lipocine Inc. (NASDAQ:LPCN) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.28 and traded as low as $4.56. Lipocine shares last traded at $4.88, with a volume of 41,591 shares traded.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. StockNews.com initiated coverage on shares of Lipocine in a report on Wednesday. They issued a “hold” rating on the stock. Alliance Global Partners started coverage on shares of Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective for the company.

Lipocine Trading Down 0.4 %

The company has a market capitalization of $25.99 million, a P/E ratio of -6.39 and a beta of 1.24. The stock’s 50-day moving average price is $5.08 and its 200-day moving average price is $5.28.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Sell-side analysts expect that Lipocine Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.